Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.8250
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
0.8356
+0.0106 (1.28%)
After-hours: Mar 28, 2025, 7:46 PM EDT
Kronos Bio Revenue
In the year 2024, Kronos Bio had annual revenue of $9.85M with 56.62% growth. Kronos Bio had revenue of $2.27M in the quarter ending December 31, 2024, a decrease of -0.70%.
Revenue (ttm)
$9.85M
Revenue Growth
+56.62%
P/S Ratio
5.03
Revenue / Employee
$984,800
Employees
10
Market Cap
50.30M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
KRON News
- 12 days ago - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 months ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 4 months ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 5 months ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 months ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 months ago - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - GlobeNewsWire
- 6 months ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 6 months ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire